Home > Steve Shak, ASCO 2020: The Oncotype DX Breast Recurrence Score® Test
Breast Cancer

Steve Shak, ASCO 2020: The Oncotype DX Breast Recurrence Score® Test

Published Online: June 5th 2020

It was a pleasure to speak to Steve Shak from Exact Sciences anto discuss the real-world evidence from a prospective clinical survey of the Oncotype DX Breast Recurrence Score® test, accepted at the ASCO Annual Meeting. Oncotype DX is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.


1. Could you give us a brief description of the Oncotype DX Breast Recurrence Score assay and its role in guiding breast cancer treatment decisions? (0:06)

2. Could you summarise the data that its being presented at this year’s ASCO conference? (1:10)

3. What has been the impact of the Oncotype DX test on clinical practice worldwide? (2:21)

4. What progress has been made on making the Oncotype DX test available on a broader international scale? (4:30)

5. What advances do you expect to see in the future with these types of biomarker assays? (7:00)


Speaker disclosure: Steve Shak is Chief Medical Officer of Exact Sciences

Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.


Share this Video
Related Videos In Breast Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar